Human Melanoma-associated antigen 1(MAGEA1) ELISA kit

Instructions
Code CSB-EL013323HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name melanoma antigen family A, 1 (directs expression of antigen MZ2-E)
Alternative Names Antigen MZ2 E ELISA Kit; Antigen MZ2-E ELISA Kit; Cancer/testis antigen 1.1 ELISA Kit; cancer/testis antigen family 1, member 1 ELISA Kit; CT1.1 ELISA Kit; MAGA1_HUMAN ELISA Kit; MAGE 1 antigen ELISA Kit; MAGE-1 antigen ELISA Kit; MAGE1 ELISA Kit; MAGE1A ELISA Kit; MAGEA1 ELISA Kit; Melanoma antigen 1 ELISA Kit; Melanoma antigen family A 1 (directs expression of antigen MZ2 E) ELISA Kit; Melanoma antigen family A 1 ELISA Kit; Melanoma antigen MAGE 1 ELISA Kit; Melanoma associated antigen 1 ELISA Kit; Melanoma associated antigen MZ2 E ELISA Kit; Melanoma-associated antigen 1 ELISA Kit; MGC9326 ELISA Kit
Abbreviation MAGEA1
Uniprot No. P43355
Species Homo sapiens (Human)
Sample Types serum, urine, tissue homogenates
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.8 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human MAGEA1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %94
Range %90-98
1:2Average %89
Range %83-93
1:4Average %97
Range %92-102
1:8Average %93
Range %86-98
Recovery
The recovery of human MAGEA1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 8580-89
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
20002.838 2.852 2.845 2.729
10002.140 2.015 2.078 1.962
5001.416 1.431 1.424 1.308
2500.903 0.939 0.921 0.805
1250.516 0.504 0.510 0.394
62.50.330 0.321 0.326 0.210
31.250.264 0.265 0.265 0.149
00.119 0.112 0.116
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.
Gene References into Functions
  1. The expression of MAGE-A genes in peripheral blood may act as a poor prognostic marker in patients with lung cancer. PMID: 29430849
  2. MAGE-A expression in blood or bone marrow at tumor surgery is an independent predictor of survival in resected non-small cell lung cancer PMID: 27542766
  3. Authors revealed a novel interaction between MAGEA1 and the intracellular segment of NOTCH1 receptor (NICD1). MAGEA1 reduced NICD1's stability by promoting the ubiquitin modification of NICD1. PMID: 28459460
  4. In patients with Colon cancer, the expression of MAGE-A(1-6) gene was associated with a poor prognosis. PMID: 28631709
  5. MAGEA1 was expression in 15% of synovial sarcomas and was not associated with prognosis. PMID: 27993576
  6. Data show that overall survival (OS) was significantly lower for patients expressing pan-MAGE or MAGE-A1/A3/A4 in both independent cohorts. PMID: 28146422
  7. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. PMID: 28677424
  8. up-regulation of MAGE-A1 dramatically promoted proliferation, migration, and invasion of human melanoma cell lines in vitro PMID: 27045082
  9. The overall survival of laryngeal squamous cell carcinoma patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression. PMID: 26766421
  10. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies PMID: 27070449
  11. TRIM31 directly binds to NSE4, suggesting the existence of a TRIM31-MAGEA1-NSE4 complex reminiscent of the NSE1-NSE3-NSE4 trimer. PMID: 25590999
  12. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. PMID: 25363021
  13. DNA methylation has a dominant role in the epigenetic hierarchy governing MAGEA1 expression PMID: 23472218
  14. results show the absence and/or low expression of MAGE A1 transcripts in oral squamous cell carcinoma; presence of hypomethylation at a small level at the promoter site of MAGE A1 was detected in both oral squamous cell carcinoma and normal oral mucosa PMID: 22447174
  15. Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells. PMID: 22134685
  16. High MAGE-1 is associated with differentiated advanced gastric cancer. PMID: 21042944
  17. MAGE1 expression mediated by demethylation of MAGE1 promoter induce progression of non-small cell lung cancer. PMID: 21273595
  18. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 have a role in anti-tumor immunity against gastric cancer PMID: 20420712
  19. Tumor-specific antigen MAGE may play a role in the occurrence and development of ovarian cancerc and can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer. PMID: 20423514
  20. MAGE-A peptides and HLA class I molecules are expressed in hepatocellular carcinoma PMID: 20592351
  21. The high expression rates of MAGE-1 and MAGE-3 genes in IHCC suggests the MAGE-1 and MAGE-3 gene may be a target for immunotherapy in IHCC patients. PMID: 18505125
  22. Since 37% of patients with operable NSCLC harbored disseminated tumor cells that expressed MAGE-A, only these patients might benefit from adjuvant immunotherapies directed against MAGE-A1 to -A6. PMID: 19467731
  23. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. PMID: 12443884
  24. Spontaneous in vivo priming of MAGE-specific T cell response and high frequency of MAGE1 and MAGE3 expression in hepatocellular carcinoma makes this antigen potential candidate for MAGE-specific immunotherapy in hepatocellular carcinoma. PMID: 14672620
  25. MAGE-A1 can function as a potent transcriptional repressor via interactions with Ski Interacting Protein and the deacetylase HDAC1. PMID: 15316101
  26. a novel sequence-specific DNA-protein interaction at the -30 CpG dinucleotide upstream of the gene was found having a vital part to play in the DNA methylation mediated transcription silencing of the MAGE-A1 gene PMID: 15353125
  27. Present, by immunocytochemistry, in normal prostate, prostatic hypertrophy and prostate cancer. PMID: 16114059
  28. down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells PMID: 16497664
  29. Detection of aberrant methylation patterns of MAGEs CpG islands using Methylation-special PCR may be useful for diagnosis of Hepatocellular Carcinoma. PMID: 16516880
  30. The promoter hypomethylation of MAGE-A1 and MAGE-A3 genes up-regulates its expression in colorectal carcinomas as well as in gastric cancers and might play a significant role in the development and progression of human colorectal carcinomas. PMID: 17007017
  31. MAGE-A1 and NY-ESO-1 are associated with highly proliferating germ cells, whereas GAGE proteins have a more general function in germ cells unrelated to any specific developmental stage PMID: 17208940
  32. Results suggest that although MAGE-A1 does not participate directly in the drug-resistant phenotype, the expression of MAGE-A1 could be a marker for the prediction of resistance to taxan-based chemotherapies in patients with gastric cancers. PMID: 17611652
  33. These data show, for the first time, the involvement of methyl-CpG binding domain proteins in the regulation of the MAGE-A genes. PMID: 17634428
  34. Report genetic alterations of MAGE A1 in Korean colorectal cancer patients. PMID: 17704924
  35. demethylation of MAGE-A1 by Mouse embryonic stem cells PMID: 18094622
  36. Multiple simultaneous detection of MAGE-A [subtypes] more specific and sensitive than detection of single MAGE-A antigen for the diagnostic and prognostic evaluation of oral squamous cell carcinoma PMID: 18197853
  37. The protective effect of the expression of the MAGE-A1 gene against tumoral progression of neuroblastoma is confirmed. PMID: 18820946
  38. Treatment of A2780/cp70 with decitabine and belinostat results in a marked increase in expression of epigenetically silenced MLH1 and MAGE-A1 both in vitro and in vivo when compared with decitabine alone. PMID: 19259094

Show More

Hide All

Subcellular Location Cytoplasm, Nucleus
Tissue Specificity Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes. Never expressed in kidney tumors, leukemias and lymphomas.
Database Links

HGNC: 6796

OMIM: 300016

KEGG: hsa:4100

STRING: 9606.ENSP00000349085

UniGene: Hs.72879

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1